Pharma Program
We are developing a novel, broad-spectrum, topical anti-infective for the treatment of skin and wound infections and the prevention of Staphylococcus aureus Our pre-clinical data have shown that our lead molecules are capable of treating Trichophyton infections and hold great promise for multiple dermatological indications.
A summary of Helix BioMedix Drug Discovery and Development Programs focusing on the Company’s initial candidates in the areas of anti-infective, anti-fungal and MRSA fighting peptides based on the innate immune system…click to learn more.
We are developing a novel, broad-spectrum, topical anti-infective for the treatment of skin and wound infections and the prevention of Staphylococcus aureus. Our pre-clinical data have shown that our lead molecules are capable of treating Trichophyton infections and hold great promise for multiple dermatological indications…click to learn more.
Our pre-clinical data have shown that our lead molecules are capable of treating Trichophyton infections and hold great promise for multiple dermatological indications…click to learn more.
Acne, rosacea, fungal conditions and MRSA are common problems facing today’s dermatologists…click to learn more.

Anti-Infective

Our Anti-Infective programs are based upon a first-in-class family of molecules known as lipohexapeptides (or small molecule peptides) that we developed to specifically combine the attributes of small molecule natural products with the advantages of antimicrobial peptides. This new class of anti-infective peptide has demonstrated significant improvement in activity, both in vitro and in vivo, over traditional antimicrobial peptides.


Anti-Infective HB1345 – Topical antibacterial

HB1345 is a synthetic lipohexapeptide anti-infective product with potent and broad spectrum antimicrobial activity when applied topically to skin infections. Although HB1345 has commercial potential in the treatment of several dermatological conditions, acne has been chosen as the lead indication because HB1345 offers a major step forward in the treatment of this condition.

Prescription drugs for acne treatment fall into three general categories: antibiotics, retinoids and drugs that affect hormone levels. Problems exist with most of these treatment options. Antibiotics are not as useful as they once were as Propionibacterium acnes (P.acnes), the bacterium most commonly associated with acne, has developed resistance to many antibiotics. Hence, a significant market exists for an innovative, effective and safe topical agent that has no side effects and avoids the problem of antibiotic resistance.

HB1345 exhibits MIC values in the 1-2ug/ml range against key pathogens, including P.acnes. It avoids the problems of the standard of care topical anti-infectives since it is cidal, non-cross resistant, exhibits low to no resistance emergence, it is active in serum and lipid mixtures (replicating conditions in the acne pore) and has an extended post-antibiotic effect. In addition, HB1345 binds to lipoteichoic acid (LTA) which is a major cause of inflammation in acne. Hence, HB1345 has significant potential in dealing with two of the three mediators of acne, P.acnes and inflammation.

HB1345 has demonstrated significant advantages over products both on the market and in development. It has the potential to fulfill the unmet medical needs in the treatment of acne.